Protein kinase downregulators have seen significant progress since the approval of imatinib, yet challenges persist in drug discovery, including high failure rates, side effects, and drug resistance issues. Multidisciplinary efforts have led to the application of new approaches to address these challenges and improve kinase downregulator discovery. Advances have been made in drug design strategies, drug property evaluation technologies, and efficacy evaluation models and technologies. These advancements aim to enhance in vitro and in vivo drug evaluation processes for more clinically relevant outcomes. This article reviews the recent progress in this field and discusses the challenges and future perspectives in developing kinase downregulator drugs.
Kinases play a vital role in signal transduction processes, regulating various cellular functions through phosphorylation. The human kinome consists of 518 protein kinases, including typical and atypical kinases. Typical kinases can be further classified into eight major groups based on their kinase domains, while atypical kinases lack this domain but still exhibit kinase activity. Understanding the diversity and classification of kinases is crucial for developing targeted kinase downregulators to modulate cellular functions and treat diseases. The structural characteristics of kinases, such as the ATP-binding pocket and catalytic residues, are essential for designing effective kinase inhibitors.
The development of kinase inhibitors has led to the approval of several drugs for clinical use. These inhibitors can compete for ATP binding in the active site of kinases, classified as type I and type II inhibitors, or target allosteric sites adjacent to the ATP pocket. However, challenges such as drug resistance and off-target effects persist. To overcome these challenges, new strategies like covalent binding, molecular glue degraders, and PROTACs have emerged. Covalent binding inhibitors form irreversible bonds with target kinases, enhancing specificity and efficacy. PROTACs induce ubiquitin-dependent protein degradation, offering a promising approach to overcome drug resistance and enhance selectivity.
Allosteric inhibitors represent another promising avenue for kinase downregulation, targeting sites outside the ATP pocket to improve selectivity and overcome drug resistance. These inhibitors can be categorized into type III and type IV based on their binding modes. The design and optimization of allosteric inhibitors have shown potential in overcoming limitations associated with ATP-competitive inhibitors. Understanding the structural and functional aspects of kinases and their inhibitors is essential for advancing drug discovery and development in this field. Challenges such as drug resistance, off-target effects, and selectivity continue to drive innovation in kinase downregulator research.
Key Takeaways:
1. Kinase downregulator discovery has advanced through multidisciplinary efforts to address challenges like drug resistance and side effects.
2. New drug design strategies, including covalent binding and allosteric inhibition, offer promising approaches to enhance kinase inhibitor efficacy.
3. Molecular glue degraders and PROTACs present innovative methods for inducing targeted protein degradation and overcoming drug resistance.
4. Understanding the structural diversity of kinases and developing selective inhibitors are critical for successful drug development in this field.
Tags: regulatory, downstream, clinical trials, mass spectrometry, immunotherapy, yeast
Read more on pmc.ncbi.nlm.nih.gov